Risk of Hepatocellular Carcinoma Development in Chronic Hepatitis C Patients Achieved Sustained Virological Response with Interferon-Based Treatments
Article Sidebar
Main Article Content
Abstract
Background: Chronic Hepatitis C (CHC) infection is a well-established risk factor for Hepatocellular Carcinoma (HCC). Even after achieving a sustained virological response (SVR) through interferon-based treatment, the risk of developing HCC persists, albeit at a lower rate. Surveillance plays a critical role in preventing HCC progression, which is often a consequence of long-term liver damage or cirrhosis due to chronic infection.
Objective: To assess the risk of hepatocellular carcinoma development in chronic hepatitis C patients who achieved sustained virological response with interferon-based treatments.
Methods: This cross-sectional descriptive study was conducted in the Department of Gastroenterology at the Asian Institute of Medical Sciences (AIMS), Hyderabad, from January to June 2024. A total of 115 patients with chronic hepatitis C who achieved SVR following interferon-based treatments were included. Initial assessments included laboratory investigations, liver biopsies, and imaging studies. Serum HCV RNA and HCV genotype were collected at the start of treatment, at the end of treatment, and 24 weeks post-treatment. Follow-up was defined as the time from the completion of treatment to the date of HCC detection or the last available imaging if no HCC was detected. Data were analyzed using SPSS version 26.0, with significance set at P<0.05.
Results: The study included 115 patients, with a mean age of 53.68 years; 54.8% were males, and 45.2% were females. Hepatocellular carcinoma was detected in 7 patients (6.1%). Genotype 2 had the highest rate of HCC occurrence at 16.7%, followed by genotype 1 at 5.6%; no HCC cases were found in genotype 3 (P=0.198). HCC incidence was higher in stage F0 fibrosis (18.8%) compared to stage F4 fibrosis (14.3%), with no cases in stages F3, F5, or F6 (P=0.292).
Conclusion: Despite achieving sustained virological response with interferon-based treatments, some chronic hepatitis C patients developed hepatocellular carcinoma. The risk of HCC remains, particularly in older patients and those with advanced liver fibrosis. Continuous monitoring and follow-up are essential for early detection and management of HCC. Further research is needed to identify specific risk factors and improve post-treatment care.
Article Details
This work is licensed under a Creative Commons Attribution 4.0 International License.
References
Ozdogan O, Yaras S. The Long-Term (10.6 Years) Outcome of Hepatitis C Patients with Sustained Virologic Response Following Treatment with Pegylated Interferon + Ribavirin. Viral Hepat J. 2020;26(1):22-7.
Nagaoki Y, Aikata H, Nakano N, Shinohara F, Nakamura Y, Hatooka M, et al. Development of Hepatocellular Carcinoma in Patients with Hepatitis C Virus Infection Who Achieved Sustained Virological Response Following Interferon Therapy: A Large-Scale, Long-Term Cohort Study. J Gastroenterol Hepatol. 2016;31(5):1009-15.
Karabulut N, Alacam S, Yolcu A, Onel M, Agacfidan A. Distribution of Hepatitis C Virus Genotypes in Istanbul, Turkey. Indian J Med Microbiol. 2018;36(2):192-6.
Ferlay J, Colombet M, Soerjomataram I, Mathers C, Parkin DM, Piñeros M, et al. Estimating the Global Cancer Incidence and Mortality in 2018: GLOBOCAN Sources and Methods. Int J Cancer. 2019;144(8):1941-53.
Zamzam ML. Epidemiologic and Clinicopathologic Features of Advanced Hepatocellular Carcinoma. J Cancer Ther. 2019;10(6):411.
Carr BI, Guerra V. Serum Albumin Levels in Relation to Tumor Parameters in Hepatocellular Carcinoma Patients. Int J Biol Markers. 2017;32(4):391-6.
Calvaruso V, Cabibbo G, Cacciola I, Petta S, Madonia S, Bellia A, et al. Incidence of Hepatocellular Carcinoma in Patients with HCV-Associated Cirrhosis Treated with Direct-Acting Antiviral Agents. Gastroenterology. 2018;155(2):411-21.
Ioannou GN, Green PK, Beste LA, Mun EJ, Kerr KF, Berry K. Development of Models Estimating the Risk of Hepatocellular Carcinoma After Antiviral Treatment for Hepatitis C. J Hepatol. 2018;69(5):1088-98.
Semmler G, Meyer EL, Kozbial K, Schwabl P, Hametner-Schreil S, Zanetto A, et al. HCC Risk Stratification After Cure of Hepatitis C in Patients with Compensated Advanced Chronic Liver Disease. J Hepatol. 2022;76(4):812-21.
Yang JD, Aqel BA, Pungpapong S, Gores GJ, Roberts LR, Leise MD. Direct Acting Antiviral Therapy and Tumor Recurrence After Liver Transplantation for Hepatitis C-Associated Hepatocellular Carcinoma. J Hepatol. 2016;65(4):859-60.
El-Serag HB, Kanwal F. Epidemiology of Hepatocellular Carcinoma in the United States: Where Are We? Where Do We Go? Hepatology. 2014;60(5):1767-75.
Ioannou GN, Green PK, Berry K. HCV Eradication Induced by Direct-Acting Antiviral Agents Reduces the Risk of Hepatocellular Carcinoma. J Hepatol. 2018;68(1):25-32.
Morgan RL, Baack B, Smith BD, Yartel A, Pitasi M, Falck-Ytter Y. Eradication of Hepatitis C Virus Infection and the Development of Hepatocellular Carcinoma: A Meta-Analysis of Observational Studies. Ann Intern Med. 2013;158(5_Part_1):329-37.
Cheung MC, Walker AJ, Hudson BE, Verma S, McLauchlan J, Mutimer DJ, et al. Outcomes After Successful Direct-Acting Antiviral Therapy for Patients with Chronic Hepatitis C and Decompensated Cirrhosis. J Hepatol. 2016;65(4):741-7.
Van Der Meer AJ, Veldt BJ, Feld JJ, Wedemeyer H, Dufour JF, Lammert F, et al. Association Between Sustained Virological Response and All-Cause Mortality Among Patients with Chronic Hepatitis C and Advanced Hepatic Fibrosis. JAMA. 2012;308(24):2584-93.
Singal AG, Lampertico P, Nahon P. Epidemiology and Surveillance for Hepatocellular Carcinoma: New Trends. J Hepatol. 2020;72(2):250-61.
Ji F, Yeo YH, Wei MT, Ogawa E, Enomoto M, Lee DH, et al. Sustained Virologic Response to Direct-Acting Antiviral Therapy in Patients with Chronic Hepatitis C and Hepatocellular Carcinoma: A Systematic Review and Meta-Analysis. J Hepatol. 2019;71(3):473-85.
Waziry R, Hajarizadeh B, Grebely J, Amin J, Law M, Danta M, et al. Hepatocellular Carcinoma Risk Following Direct-Acting Antiviral HCV Therapy: A Systematic Review, Meta-Analyses, and Meta-Regression. J Hepatol. 2017;67(6):1204-12.
Bahadır Ö, Saltürk A, Kıyak M, Şahin H, Kanatsız E, Ceran N, et al. Risk of Hepatocellular Carcinoma Development in Chronic Hepatitis C Patients Who Achieved a Sustained Virological Response with Interferon-Based Treatments. Med J Haydarpaşa Numune Training Res Hosp. 2022;63(3):0-.
Luna-Cuadros MA, Chen HW, Hanif H, Ali MJ, Khan MM, Lau DT. Risk of Hepatocellular Carcinoma After Hepatitis C Virus Cure. World J Gastroenterol. 2022;28(1):96.
Sharaf AL, Elbadrawy EG, Abdellatif AM, Abd Al Monem N. Frequency of Hepatocellular Carcinoma in Cirrhotic Patients After Chronic Hepatitis C Infection Treatment with Direct-Acting Antivirals. Afro Egypt J Infect Endemic Dis. 2022;12(1):16-23.
Tariq M, Ahad W, Tahir M, Ahmed A, Shafique HM. Frequency of Hepatocellular Carcinoma in Cirrhotic Patients with Hepatitis-C Virus Positive Patients in Karachi-Pakistan. Int J Res Med Sci. 2015;3(7):1594-8.